Literature DB >> 7499190

Preferential involvement of MEK1 in the tumor necrosis factor-alpha-induced activation of p42mapk/erk2 in mouse macrophages.

B W Winston1, L K Remigio, D W Riches.   

Abstract

The pleiotropic cytokine tumor necrosis factor-alpha (TNF alpha) controls the expression of multiple gene products in macrophages and plays an important role in host defense. TNF alpha is recognized by the receptors, CD120a (p55) and CD120b (p75). Ligation of CD120a (p55) by TNF alpha or by anti-receptor agonistic antibodies initiates signal transduction leading to the activation of mitogen-activated protein kinases (MAPKs) (p42mapk/erk2 and p44mapk/erk1). Phosphorylation and activation of MAPK are mediated by MAPK kinase (MEK), a family of Thr/Tyr kinases. In this study, we investigated the preferential involvement of the MEK isoforms MEK1 and MEK2 in the activation of p42mapk/erk2 in mouse macrophages stimulated with TNF alpha. Exposure of macrophages to TNF alpha stimulated a time-dependent increase in the activity of MEK1 as measured by an in vitro kinase assay using kinase-inactive p42mapk/erk2 (rMAPKkd) as substrate in the presence of gamma-[32P]ATP. Maximal activation of MEK1 was detected at 10 min poststimulation and coincided with maximal transphosphorylation of Tyr and Thr residues of rMAPKkd. By contrast, there was no evidence of MEK2 activation in macrophages in response to TNF alpha. These data suggest that MEK1 is the preferred substrate for MEK kinase, the upstream kinase implicated in activation of the MAPK pathway in macrophages by TNF alpha.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499190     DOI: 10.1074/jbc.270.46.27391

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Alcohol abuse and disorder of granulopoiesis.

Authors:  Xin Shi; Angelo L DeLucia; Jianxin Bao; Ping Zhang
Journal:  Pharmacol Ther       Date:  2019-03-01       Impact factor: 12.310

2.  Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF alpha.

Authors:  E D Chan; B W Winston; M B Jarpe; M W Wynes; D W Riches
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-kappaB signaling pathways.

Authors:  E D Chan; K R Morris; J T Belisle; P Hill; L K Remigio; P J Brennan; D W Riches
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Antileishmanial effect of 18β-glycyrrhetinic acid is mediated by Toll-like receptor-dependent canonical and noncanonical p38 activation.

Authors:  Purnima Gupta; Pijush K Das; Anindita Ukil
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  Mek2 is dispensable for mouse growth and development.

Authors:  Louis-François Bélanger; Sophie Roy; Michel Tremblay; Barbara Brott; Ann-Muriel Steff; Walid Mourad; Patrice Hugo; Raymond Erikson; Jean Charron
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

Review 6.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling.

Authors:  D T Denhardt
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages.

Authors:  Asima Bhattacharyya; Shresh Pathak; Simanti Datta; Santanu Chattopadhyay; Joyoti Basu; Manikuntala Kundu
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

8.  Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway.

Authors:  M Kashiwada; Y Shirakata; J I Inoue; H Nakano; K Okazaki; K Okumura; T Yamamoto; H Nagaoka; T Takemori
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.